IRAG1

Across TCGA pan-cancer cohorts, IRAG1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IRAG1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IRAG1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRAG1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where IRAG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.836	0.452	.017	6	view →
CCRCC	DFS	Median	III,IV	0.729	0.453	.028	4	view →
LUAD	OS	Median	II,III,IV	0.470	0.851	.026	3	view →
LSCC	DFS	Median	II,III,IV	0.675	0.880	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IRAG1–PDAC (DFS)

Open the PDAC breakdown →